Physician profile
Jay S Maizes
NPI 1821045642
$6,416.47
in general payments reported to CMS, 2019-2025
33 companies · $1,931 in 2025
The $1,931 reported for 2025 was more than what 75% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $356 · 2020: $459 · 2021: $446 · 2022: $635 · 2023: $1,194 · 2024: $1,395 · 2025: $1,931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,419 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,418.59 |
| Education | $101.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,241.79 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $942.11 | 2019-2025 | Ofev, Stiolto Respimat, Jascayd |
| Astrazeneca Pharmaceuticals LP | $755.06 | 2020-2025 | Fasenra, Breztri, Airsupra |
| Grifols USA, LLC | $408.70 | 2019-2025 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $373.50 | 2022-2025 | Glassia |
| Ani Pharmaceuticals, INC. | $362.51 | 2023-2025 | Purified Cortrophin Gel |
| Inogen, INC. | $248.05 | 2022-2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Insmed, INC. | $218.44 | 2022-2025 | Arikayce, Brinsupri |
| Vifor Pharma, INC. | $201.69 | 2024-2025 | Zemaira |
| Mallinckrodt Hospital Products INC. | $195.45 | 2023-2025 | Acthar |
| Regeneron Healthcare Solutions, INC. | $172.30 | 2019-2025 | Dupixent |
| Jazz Pharmaceuticals INC. | $141.30 | 2023-2025 | Xywav |
| Inspire Medical Systems, INC. | $133.82 | 2021-2024 | Inspire |
| Actelion Pharmaceuticals US, INC. | $126.57 | 2023-2025 | Opsumit, Uptravi, Opsynvi |
| Mylan Specialty L.P. | $126.27 | 2019-2023 | Yupelri |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $122.02 | 2023-2025 | |
| Harmony Biosciences LLC | $85.54 | 2023-2025 | Wakix |
| Sanofi-Aventis U.S. LLC | $79.99 | 2022 | |
| Amgen INC. | $70.58 | 2023-2025 | Tezspire |
| United Therapeutics Corporation | $50.53 | 2021 | |
| Axsome Therapeutics, INC. | $47.00 | 2023-2024 | Sunosi |
| Genentech USA, INC. | $39.95 | 2019 | |
| Ethicon INC. | $37.40 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $32.59 | 2021-2024 | Keytruda |
| Covis Pharma Gmbh | $30.76 | 2022 | |
| Verona Pharma, INC. | $30.58 | 2025 | Ohtuvayre |
| Resmed Corp | $29.98 | 2023 | |
| Paratek Pharmaceuticals, INC. | $24.26 | 2024 | Nuzyra |
| Baxter Healthcare | $21.26 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Teva Pharmaceuticals USA, INC. | $21.15 | 2020 | |
| Optinose US, INC. | $19.27 | 2019 | |
| Lilly USA, LLC | $13.96 | 2025 | Zepbound |
| Ambu INC. | $12.09 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Maizes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.